Young Adults May Soon Be Able to Get an RSV ShotPfizer's RSV shot showed strong immune reactions in young adults at higher risk, prompting plans for extended U.S. approval.The adult vaccine market for RSV is expected to be lucrative, with Pfizer aiming to increase its market share.